ERBB2 and breast cancer: Additionally, with DESTINY-Breast06 demonstrating response to ADC therapy of ERBB2-ultralow HR-positive BC (defined as IHC 0 with membrane staining),45 the significance of ERBB2-ultralow expression in patients with TNBC warrants future investigation.